For immediate release |
4 November 2008 |
Advanced Medical Solutions Group plc
('AMS' or 'the Company')
Holding in Company
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, received notification on 30 October 2008 from Mr J D Slater and family that following recent share purchases they are interested in 8,730,000 ordinary shares of 5 pence each in the Company, representing 6.09 per cent of the Company's issued share capital.
For further information, please contact:
Advanced Medical Solutions Group plc |
|
Don Evans, Chief Executive Officer Mary Tavener, Finance Director |
Tel: +44 (0) 1606 545508 |
|
|
Buchanan Communications |
Tel: +44 (0) 20 7466 5000 |
Mark Court, Mary-Jane Johnson, Stasa Filipic Teathers Shaun Dobson / Claes Spang |
Tel: +44 (0) 20 7426 9000 |
Notes to Editors:
Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.
Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.
In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.
The acquisition of 49.4% of Corpura BV in May 2008 strengthened AMS' position in hydrophilic polyurethane foam - the largest and fastest growing segment of the advanced woundcare market
AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection.
AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.